Literature DB >> 15001811

G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice.

Laura M Bohn1, Raul R Gainetdinov, Marc G Caron.   

Abstract

G protein-coupled receptors (GPCRs) currently represent pharmaceutical targets for numerous medicinal compounds that are used to treat conditions ranging from blood pressure dysregulation to depression to pain, demonstrating the wide range of functions mediated by this receptor family. GPCR activation is determined not only by the initiation of signaling cascades but also by regulatory mechanisms that control the extent and duration of their signals. The balance of activation and desensitization dictate the ultimate physiological response to both endogenous and exogenous receptor stimuli. Therefore, these mechanisms may play a particularly relevant role during chronic exposure to agonists such as in conditions when drugs are abused. Two major classes of drugs of abuse, opiates and psychostimulants, both use either direct or indirect GPCR signaling mechanisms to mediate their effects. Therefore, the regulation of GPCRs may have bearing on the neuronal adaptations that underlie the reinforcing properties of drugs of abuse.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001811     DOI: 10.1385/NMM:5:1:041

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  64 in total

Review 1.  New insights into dopaminergic receptor function using antisense and genetically altered animals.

Authors:  D R Sibley
Journal:  Annu Rev Pharmacol Toxicol       Date:  1999       Impact factor: 13.820

Review 2.  Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization.

Authors:  J Zhang; S S Ferguson; L S Barak; M J Aber; B Giros; R J Lefkowitz; M G Caron
Journal:  Receptors Channels       Date:  1997

3.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

4.  Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain.

Authors:  M Erdtmann-Vourliotis; P Mayer; S Ammon; U Riechert; V Höllt
Journal:  Brain Res Mol Brain Res       Date:  2001-11-01

5.  Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity.

Authors:  M A Hurlé
Journal:  J Neurochem       Date:  2001-04       Impact factor: 5.372

6.  beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation.

Authors:  D A Conner; M A Mathier; R M Mortensen; M Christe; S F Vatner; C E Seidman; J G Seidman
Journal:  Circ Res       Date:  1997-12       Impact factor: 17.367

7.  Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice.

Authors:  Laura M Bohn; Robert J Lefkowitz; Marc G Caron
Journal:  J Neurosci       Date:  2002-12-01       Impact factor: 6.167

8.  Morphine activates opioid receptors without causing their rapid internalization.

Authors:  D E Keith; S R Murray; P A Zaki; P C Chu; D V Lissin; L Kang; C J Evans; M von Zastrow
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

9.  Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine.

Authors:  Y M Wang; R R Gainetdinov; F Fumagalli; F Xu; S R Jones; C B Bock; G W Miller; R M Wightman; M G Caron
Journal:  Neuron       Date:  1997-12       Impact factor: 17.173

10.  Agonist-selective endocytosis of mu opioid receptor by neurons in vivo.

Authors:  C Sternini; M Spann; B Anton; D E Keith; N W Bunnett; M von Zastrow; C Evans; N C Brecha
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

View more
  19 in total

Review 1.  Functional selectivity of GPCR signaling in animals.

Authors:  Lei Zhou; Laura M Bohn
Journal:  Curr Opin Cell Biol       Date:  2013-12-22       Impact factor: 8.382

Review 2.  Mu opioid receptor regulation and opiate responsiveness.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

Review 3.  Look before leaping: combined opioids may not be the rave.

Authors:  Mellar P Davis; Susan B LeGrand; Ruth Lagman
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

Review 4.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

5.  The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats.

Authors:  C Austin Zamarripa; Shelley R Edwards; Hina N Qureshi; John N Yi; Bruce E Blough; Kevin B Freeman
Journal:  Drug Alcohol Depend       Date:  2018-09-18       Impact factor: 4.492

6.  Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology.

Authors:  Kenneth Lamb; Kevin Tidgewell; Denise S Simpson; Laura M Bohn; Thomas E Prisinzano
Journal:  Drug Alcohol Depend       Date:  2011-11-26       Impact factor: 4.492

7.  Phosphorylation barcode-dependent signal bias of the dopamine D1 receptor.

Authors:  Ali I Kaya; Nicole A Perry; Vsevolod V Gurevich; T M Iverson
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-05       Impact factor: 11.205

Review 8.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

9.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

Review 10.  β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  Handb Exp Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.